Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amg-319. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 17/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amg-319 SCHEMBL4185718 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| Amg-319 SCHEMBL17240940 | 0.99 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL10250907 | 0.90 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL27781218 | 0.90 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL4173756 | 0.90 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL28786259 | 0.89 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL12005462 | 0.89 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL4174885 | 0.88 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL4182647 | 0.88 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL10252032 | 0.88 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-20170266191-A1 | Therapeutic Combination of PI3K Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-09-21 | — | — | US | claimed |
| EP-3076974-A1 | THERAPEUTIC COMBINATION OF A PI3K INHIBITOR AND A BTK INHIBITOR | Acerta Pharma B.V. (NL) | 2016-10-12 | — | — | EP | claimed |
| WO-2015083008-A1 | THERAPEUTIC COMBINATION OF A PI3K INHIBITOR AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2015-06-11 | — | — | WO | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| EP-3179992-B1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA BV (NL) | 2022-05-11 | — | — | EP | disclosed |
| WO-2016128912-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR, AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016024230-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024228-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024232-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR AND/OR A CDK 4/6 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024231-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015171725-A1 | HYDRATE, CRYSTALLINE HYDRATE AND CRYSTALLINE ANHYDRATE FORMS OF N-((1S)-1-(7-FLUORO-2-(2-PYRIDINYL)-3-QUINOLINYL)ETHYL)-9H-PURIN-6-AMINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR TREATING CANCER. | AMGEN INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| CN-101715453-B | Heterocyclic compounds and their uses | AMGEN INC | 2012-06-27 | — | — | CN | disclosed |
| CN-101715453-A | Heterogeneous ring compound and application thereof | AMGEN INC | 2010-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | PIK3CD 97/4885PIK3CG 146/4885PIK3CB 207/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | PIK3CD 37/4885PIK3CG 47/4885PIK3CB 73/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | PIK3CD 202/4885PIK3CG 302/4885PIK3CB 276/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | PIK3CD 10/4885PIK3CG 18/4885PIK3CB 31/4885 |
| US-20170266191-A1 | Therapeutic Combination of PI3K Inhibitor and a BTK Inhibitor | BTK, SYK, PIK3CD | PIK3CD 3/4885PIK3CG 9/4885PIK3CB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.